Clinical Trial Detail

NCT ID NCT03213691
Title Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

histiocytosis

non-Hodgkin lymphoma

neuroblastoma

Therapies

Selumetinib

Age Groups: adult child

Additional content available in CKB BOOST